First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

NCT07216066 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinsons Disease

Interventions

DRUG: ALN-SNCA
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals